Company Quick10K Filing
Laboratory of America
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 99 $16,943
10-Q 2019-10-31 Quarter: 2019-09-30
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-03 Quarter: 2019-03-31
10-K 2019-02-28 Annual: 2018-12-31
10-Q 2018-10-30 Quarter: 2018-09-30
10-Q 2018-07-27 Quarter: 2018-06-30
10-Q 2018-05-01 Quarter: 2018-03-31
10-K 2018-02-27 Annual: 2017-12-31
10-Q 2017-11-02 Quarter: 2017-09-30
10-Q 2017-08-02 Quarter: 2017-06-30
10-Q 2017-04-28 Quarter: 2017-03-31
10-K 2017-02-27 Annual: 2016-12-31
10-Q 2016-10-28 Quarter: 2016-09-30
10-Q 2016-07-29 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-02-29 Annual: 2015-12-31
10-Q 2015-10-30 Quarter: 2015-09-30
10-Q 2015-07-30 Quarter: 2015-06-30
10-Q 2015-05-04 Quarter: 2015-03-31
10-K 2015-02-26 Annual: 2014-12-31
10-Q 2014-11-10 Quarter: 2014-09-30
10-Q 2014-07-29 Quarter: 2014-06-30
10-Q 2014-04-29 Quarter: 2014-03-31
10-K 2014-02-25 Annual: 2013-12-31
10-Q 2013-10-28 Quarter: 2013-09-30
10-Q 2013-07-30 Quarter: 2013-06-30
10-Q 2013-05-01 Quarter: 2013-03-31
10-K 2013-02-26 Annual: 2012-12-31
10-Q 2012-10-30 Quarter: 2012-09-30
10-Q 2012-08-02 Quarter: 2012-06-30
10-Q 2012-04-27 Quarter: 2012-03-31
10-K 2012-02-24 Annual: 2011-12-31
10-Q 2011-10-31 Quarter: 2011-09-30
10-Q 2011-08-02 Quarter: 2011-06-30
10-Q 2011-05-04 Quarter: 2011-03-31
10-K 2011-03-01 Annual: 2010-12-31
10-Q 2010-07-27 Quarter: 2010-06-30
10-Q 2010-04-28 Quarter: 2010-03-31
10-K 2010-02-24 Annual: 2009-12-31
8-K 2020-01-13 Regulation FD, Exhibits
8-K 2020-01-06 Regulation FD, Exhibits
8-K 2019-12-03 Regulation FD, Exhibits
8-K 2019-11-25 Enter Agreement, Exhibits
8-K 2019-11-22 Officers, Regulation FD, Exhibits
8-K 2019-11-19 Regulation FD, Exhibits
8-K 2019-11-18 Regulation FD, Exhibits
8-K 2019-11-18 Other Events, Exhibits
8-K 2019-11-01 Officers, Regulation FD, Exhibits
8-K 2019-10-24 Earnings, Exhibits
8-K 2019-10-22
8-K 2019-10-15 Regulation FD
8-K 2019-10-03 Officers, Regulation FD, Other Events, Exhibits
8-K 2019-09-11 Regulation FD
8-K 2019-08-29 Regulation FD, Exhibits
8-K 2019-08-29 Regulation FD, Exhibits
8-K 2019-07-29 Regulation FD
8-K 2019-07-25 Earnings, Exhibits
8-K 2019-07-22 Regulation FD
8-K 2019-07-01 Regulation FD
8-K 2019-06-25 Regulation FD
8-K 2019-06-18 Regulation FD
8-K 2019-06-07 Regulation FD
8-K 2019-06-04 Officers, Regulation FD, Exhibits
8-K 2019-06-04 Regulation FD
8-K 2019-06-03 Enter Agreement, Off-BS Arrangement, Regulation FD, Exhibits
8-K 2019-05-10 Regulation FD
8-K 2019-05-09 Shareholder Vote
8-K 2019-05-02 Regulation FD
8-K 2019-04-30 Earnings
8-K 2019-04-17 Regulation FD, Exhibits
8-K 2019-04-01 Regulation FD
8-K 2019-04-01 Regulation FD
8-K 2019-03-28 Regulation FD
8-K 2019-03-11 Regulation FD
8-K 2019-03-05 Regulation FD
8-K 2019-02-19 Regulation FD
8-K 2019-02-07 Earnings
8-K 2019-02-07 Exhibits
8-K 2019-01-31 Officers
8-K 2019-01-22 Regulation FD
8-K 2019-01-16 Regulation FD
8-K 2019-01-15 Regulation FD
8-K 2019-01-08 Regulation FD
8-K 2019-01-03 Regulation FD
8-K 2019-01-03 Regulation FD
8-K 2019-01-03
8-K 2018-12-21 Officers
8-K 2018-12-20 Officers
8-K 2018-12-07 Regulation FD
8-K 2018-12-07 Regulation FD
8-K 2018-11-30 Regulation FD, Exhibits
8-K 2018-11-28 Regulation FD
8-K 2018-11-08 Regulation FD
8-K 2018-11-01 Regulation FD
8-K 2018-10-29 Regulation FD
8-K 2018-10-24 Exhibits
8-K 2018-10-24 Earnings
8-K 2018-10-18 Regulation FD
8-K 2018-10-18 Regulation FD
8-K 2018-10-17 Regulation FD
8-K 2018-10-10 Regulation FD
8-K 2018-10-01 Regulation FD
8-K 2018-09-25 Regulation FD
8-K 2018-09-24 Regulation FD
8-K 2018-09-24 Regulation FD
8-K 2018-09-11 Regulation FD
8-K 2018-09-06 Regulation FD
8-K 2018-07-25 Earnings
8-K 2018-07-25 Exhibits
8-K 2018-07-16 Regulation FD
8-K 2018-07-12 Regulation FD
8-K 2018-07-02 Regulation FD
8-K 2018-06-28 Regulation FD
8-K 2018-06-27 Regulation FD
8-K 2018-06-12 Regulation FD
8-K 2018-06-11 Regulation FD
8-K 2018-06-05 Regulation FD
8-K 2018-06-01 Regulation FD
8-K 2018-05-25 Regulation FD
8-K 2018-05-24 Regulation FD
8-K 2018-05-10 Shareholder Vote
8-K 2018-05-03 Regulation FD
8-K 2018-05-01 Regulation FD
8-K 2018-04-30 Regulation FD, Other Events, Exhibits
8-K 2018-04-25 Exhibits
8-K 2018-04-25 Earnings
8-K 2018-04-24 Regulation FD
8-K 2018-04-23 Regulation FD
8-K 2018-04-02 Regulation FD
8-K 2018-03-22 Regulation FD
8-K 2018-03-12 Regulation FD
8-K 2018-03-09 Regulation FD
8-K 2018-03-07 Regulation FD
8-K 2018-03-06 Regulation FD
8-K 2018-03-05 Regulation FD
8-K 2018-02-28 Regulation FD
8-K 2018-02-27 Regulation FD
8-K 2018-02-23 Regulation FD
8-K 2018-02-20 Regulation FD
8-K 2018-02-06 Earnings
8-K 2018-02-06 Regulation FD
8-K 2018-01-19 Regulation FD
8-K 2018-01-09 Regulation FD
8-K 2018-01-08 Regulation FD
8-K 2018-01-03 Regulation FD
8-K 2018-01-02 Regulation FD

Laboratory of America Financials

LH Metrics, Comps, Filings

Annual | Quarterly

Business

Laboratory Corporation of America® Holdings (LabCorp® or the Company) is a leading global life sciences company that is deeply integrated in guiding patient care. The Company provides comprehensive clinical laboratory and end-to-end drug development services through LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). LabCorp is positioned at the convergence of research and care delivery to enable more precise and individualized healthcare, bringing together world-class diagnostics and drug development capabilities. With nearly 61,000 employees worldwide, the Company's mission is to improve health and improve lives by delivering world-class diagnostics, accelerating the availability of innovative medicines to patients, and using technology to change the way care is delivered. LabCorp, an S&P 500 company, was named to FORTUNE magazine's 2019 List of World's Most Admired Companies, making the annual list for the second consecutive year.

The Company provides diagnostic, drug development and technology-enabled solutions for more than 120 million patient encounters per year. The Company typically processes tests on more than 2.5 million patient specimens per week and also supports clinical trial activity in approximately 100 countries through its industry-leading central laboratory, preclinical, and clinical development businesses, generating more safety and efficacy data to support drug approvals than any other company. CDD collaborated on 93% of the novel drugs approved by the U.S. Food and Drug Administration (FDA) in 2018, including 94% of the novel rare and orphan disease drugs and 94% of the novel oncology drugs. In addition, CDD has been involved in the development of all of the current top 50 drugs on the market as measured by sales revenue.

The Company, a Delaware corporation, is headquartered in Burlington, North Carolina, and was incorporated in 1971. Although portions of its business have an even longer history, the Company identifies its founding in 1969 and will celebrate its 50th anniversary in 2019. The Company has continually expanded and diversified its business offerings, technological expertise, geographic reach, revenue base, and financial growth opportunities through a combination of organic investments and disciplined acquisitions.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Centene (CNC) 21,833 97% 7.5 4% 34,368 22,098 69,541 67,197 1,277 2,854 21,332
Laboratory of America (LH) 16,943 28% 9.7 5% 17,744 10,580 11,292 3,177 854 2,348 22,813
WellCare Health Plans (WCG) 14,540 77% 12.1 4% 13,206 8,602 24,901 19,250 521 1,110 13,453
Quest Diagnostics (DGX) 13,740 34% 11.7 7% 11,760 6,301 7,572 2,606 781 1,489 17,443
Henry Schein (HSIC) 10,372 29% 11.4 7% 7,112 3,378 11,463 3,318 500 989 11,269
Molina Healthcare (MOH) 9,201 4% 6.7 12% 6,690 4,954 17,673 664 792 1,222 8,191
Guardant Health (GH) 7,812 0% -103.2 -9% 940 78 145 0 -81 -74 7,637
Acadia Healthcare (ACHC) 3,015 0% -221.9 -3% 6,790 4,336 3,054 0 -208 -28 6,218
Genomic Health (GHDX) 2,068 85% 28.3 12% 426 109 429 363 50 64 1,824
Invitae (NVTA) 1,958 39% -13.7 -29% 503 161 177 69 -148 -130 1,780
Natera (NTRA) 1,892 40% -18.1 -33% 383 290 273 108 -128 -107 1,935
Biotelemetry (BEAT) 1,823 62% 19.4 7% 664 317 419 262 46 101 1,968
Patterson Companies (PDCO) 1,786 29% 12.8 4% 3,350 1,846 4,130 1,197 118 190 2,420
CareDx (CDNA) 1,467 20% -39.6 -27% 143 50 102 20 -39 -36 1,423
Veracyte (VCYT) 1,282 69% 202.1 0% 252 28 109 75 0 5 1,089
Trupanion (TRUP) 1,211 17% 170.1 0% 230 99 340 58 0 7 1,202
Radnet (RDNT) 763 10% 11.6 3% 1,597 1,384 1,035 104 43 122 1,405
Hanger (HNGR) 712 0% 19.9 2% 781 803 1,065 0 12 59 1,181
Misonix (MSON) 232 70% -39.5 -25% 30 8 39 27 -7 -6 225
Celcuity (CELC) 222 -28.7 -31% 23 1 0 0 -7 -7 207

Balance Sheet ($MM)2009-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash148159467404580716434317427
Accounts Receivable5747007187858161,2181,3291,4811,468
Inventory90111121136140191205228237
PP&E5015786311,7327861,7471,7191,7491,785
Assets4,8386,1376,7956,9667,30214,22214,24716,56816,185
Accounts Payable183258237304282497508663635
Long-Term Debt9772,0862,1753,0153,0536,3565,77897
Liabilities2,7323,6134,0574,4554,4649,2628,7269,7179,195
Stockholders' Equity2,1062,5042,7172,4912,8204,9445,5066,8306,971
Income Statement ($MM)2009-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue4,6955,5425,6715,8086,0128,5069,43710,20611,333
Cost of Revenue2,7243,2683,4223,5853,8085,7776,4616,9778,157
Gross Profit1,9712,2752,2502,2232,2032,9033,1803,4643,176
R&D
SG&A9591,1601,1151,1291,1981,6221,6301,8121,571
Tax329333359340284249346-139384
Net Income5565335855755134387331,274884
Cash Flow ($MM)2009-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating8628568418197399821,1761,4591,305
Cash Investing-334-280-534-360-350-3,995-796-2,229207
Cash Financing-601-645-1-518-2013,185-650632-1,390